| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Royalty Pharma Investments 2019 ICAV | Director, 10%+ Owner | $32M | Jan 31, 2022 | ||
| Matthew Ros | Executive Vice President, Chief Strategy & Business Officer | $157K | Aug 16, 2021 | ||
| Andrew Allen | Director | $29K | Jun 11, 2021 | ||
| Kenneth Bate | Director | Aug 12, 2022 | |||
| Shefali Agarwal | Consultant and Named Executive Officer | Aug 12, 2022 | |||
| Pablo G. Legorreta | Director, 10%+ Owner | Aug 12, 2022 | |||
| Grant C. Bogle | President and CEO, Director | Aug 12, 2022 | |||
| Michael F. Giordano | Director | Aug 12, 2022 | |||
| Jerald Korn | Chief Operating Officer | Aug 12, 2022 | |||
| Joseph Beaulieu | Senior Vice President, Finance and Corporate Controller | Aug 12, 2022 | |||
| Jeffery Kutok | Chief Scientific Officer | Aug 12, 2022 | |||
| Carol Stuckley | Director | Aug 12, 2022 | |||
| Roy A. Beveridge | Director | Aug 12, 2022 | |||
| David Mott | Director | Aug 12, 2022 | |||
| Victoria Richon | Director | Aug 12, 2022 | |||
| Carl Goldfischer | Director | Aug 12, 2022 | |||
| Kevin T. Conroy | Director | Aug 12, 2022 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|